secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001171843-22-003482
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Q1 2022 net loss $7.8M ($0.23/share); cash $34.7M; clinical milestones on track
--------------------------------------------------------------------------------

- Net loss $7.8M vs $3.8M YoY; per share loss $0.23 vs $0.16; non-cash expenses $813K.
- Cash balance $34.7M at March 31, 2022; projected FY 2022 cash burn $16.8M.
- R&D expenses $5.3M (+70% YoY) and G&A $2.1M (+253% YoY) due to increased activity.
- Clinical data readouts for agenT-797 in solid tumors and ARDS on track for 2H 2022.
- GMP manufacturing launch anticipated in 1H 2022 with target 10,000 doses/yr.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184322003482/0001171843-22-003482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184322003482/f8k_051022.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer